logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5137.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5137.produseast1
Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings | Journal Article / Research | MSF Science Portal
Journal Article
|Research

Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings

Curtis A, Marshall C, Spelman T, Greig J, Elliot J, Shanks L, du Cros PAK, Casas EDT, da Fonseca M, O'Brien DP
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
OBJECTIVES
To determine the incidence of WHO clinical stage 3 and 4 conditions during early anti-retroviral therapy (ART) in resource limited settings (RLS).

DESIGN/SETTING
A descriptive analysis of routine program data collected prospectively from 25 Médecins Sans Frontières supported HIV treatment programs in eight countries between 2002 and 2010.

SUBJECTS/PARTICIPANTS
35,349 study participants with median follow-up on ART of 1.33 years (IQR 0.51-2.41).

OUTCOME MEASURES
Incidence in 100 person-years of WHO stage 3 or 4 conditions during 5 periods after ART initiation. Diagnoses of conditions were made according to WHO criteria and relied upon clinical assessments supported by basic laboratory investigations.

RESULTS
The incidence of any WHO clinical stage 3 or 4 condition over 3 years was 40.02 per 100 person-years (31.77 for stage 3 and 8.25 for stage 4). The incidence of stage 3 and 4 conditions fell by over 97% between months 0-3 and months 25-36 (77.81 to 2.40 for stage 3 and 28.70 to 0.64 for stage 4). During months 0-3 pulmonary tuberculosis was the most common condition diagnosed in adults (incidence 22.24 per 100 person-years) and children aged 5-14 years (25.76) and oral candidiasis was the most common in children <5 years (25.79). Overall incidences were higher in Africa compared with Asia (43.98 versus 12.97 for stage 3 and 8.98 versus 7.05 for stage 4 conditions, p<0.001). Pulmonary tuberculosis, weight loss, oral and oesophageal candidiasis, chronic diarrhoea, HIV wasting syndrome and severe bacterial infections were more common in Africa. Extra-pulmonary tuberculosis, non-tuberculous mycobacterial infection, cryptococcosis, penicilliosis and toxoplasmosis were more common in Asia.

CONCLUSIONS
The incidence of WHO stage 3 and 4 conditions during the early period after ART initiation in RLS is high, but greatly reduces over time. This is likely due to both the benefits of ART and deaths of the sickest patients occurring shortly after ART initiation. Access to appropriate disease prevention tools prior to ART, and early initiation of ART, are important for their prevention.

Countries

Congo-Brazzaville Democratic Republic of Congo Côte d'Ivoire Ethiopia Moldova Myanmar Nigeria Zambia Zimbabwe India

Subject Area

access to health care

Languages

English
DOI
10.1371/journal.pone.0052019
Published Date
20 Dec 2012
PubMed ID
23284857
Journal
PLOS One
Volume | Issue | Pages
Volume 7, Issue 12, Pages e52019
Issue Date
2012-12-20
Dimensions Badge